NITI Aayog has unveiled a roadmap projecting India’s bioeconomy to reach $691 billion by 2035 and $2.6 trillion by 2047. This growth strategy focuses on AI-driven biotechnology, regulatory reforms, and a proposed ₹50,000 crore growth fund. The sector, which grew from $10 billion in 2014 to $195.3 billion in 2025, is now seen as a major future contributor to national GDP and employment.
NITI Aayog has released a strategic roadmap aimed at transforming India into a global biotechnology powerhouse. The vision document, titled 'Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035,' outlines a path for the sector to achieve a valuation of $691 billion within the next nine years, eventually reaching $2.6 trillion by 2047. This initiative marks a significant policy push toward integrating biology with artificial intelligence, robotics, and advanced manufacturing to compete on a global scale.
Strategic Shift to Mission-Mode Execution
The report emphasizes that reaching these targets requires a departure from fragmented research efforts toward a unified national strategy. NITI Aayog recommends the formation of empowered committees to ensure better coordination across government ministries, industry players, and academic institutions. A core component of this strategy is the proposed ₹50,000 crore BioEconomy Growth Fund, which would provide capital for infrastructure development, innovation, and the scaling of biomanufacturing operations. The goal is to move India from traditional research models toward next-generation biomanufacturing, which is expected to support the creation of over 30 million jobs.
Scaling from 2014 to 2025
The Indian bioeconomy has demonstrated strong momentum over the last decade. Data indicates the sector expanded sixteen-fold from approximately $10 billion in 2014 to $195.3 billion by 2025. This rapid growth has already elevated the sector's contribution to 4.8% of the national GDP. While this expansion highlights the sector's potential, sustaining such growth will depend on how effectively the government addresses current bottlenecks, such as the speed of regulatory approvals and the need for specialized bioscience talent.
Global Competition and Implementation Risks
The transition to a biological-led industrial model is becoming a global priority. The United States currently utilizes a comprehensive government approach to biomanufacturing, while the European Union focuses on linking biotechnology to climate competitiveness. China has also integrated biotechnology into its national five-year industrial plans. For Indian investors, the key monitorable will be the actual rollout of the proposed BioEconomy Growth Fund and the specific regulatory reforms that follow. While the scale of the target is ambitious, successful execution faces inherent risks, including the timeline for infrastructure development, the ability to maintain competitive pricing in global markets, and the necessity of achieving a high degree of integration between AI and biological research. Investors should track future policy announcements and the allocation of funds to these specific sectors as a sign of progress toward these long-term targets.